Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

NCT06950814 | Recruiting

• 1 other identifier: JHuang20231
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Conditions

Sarcomatoid Carcinoma; Liver Cancer; Adjuvant Therapy

Outcome Measures

Primary Outcomes (1)

• Disease-free survival

  Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

  From December 2018 to May 2023

Secondary Outcomes (1)

• Overall survival

  From December 2018 to May 2023

Study Arms (2)

Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy

Procedure: postoperative adjuvant therapy

Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy

Interventions

postoperative adjuvant therapy PROCEDURE

Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.

You may qualify if:

• patients who underwent liver resection
• patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

You may not qualify if:

• patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
• patients diagnosed with other specific types of sarcomas;
• patients with concurrent other malignancies during the course of PHSC;
• patients who were lost to follow-up or lacked essential clinical data.

Sponsors & Collaborators

• West China Hospital: lead

Study Sites (1)

West China Hospital

Chengdu, Sichuan, 610041, China

RECRUITING

MeSH Terms

Conditions

Carcinoma; Liver Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Central Study Contacts

Jiwei Huang Professor

CONTACT

+86 18980606725; huangjiwei@wchscu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: April 22, 2025
• First Posted: April 30, 2025
• Study Start: April 5, 2025
• Primary Completion: May 3, 2025
• Study Completion: May 5, 2025
• Last Updated: April 30, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)